Nautilus Biotechnolgy
NAUT | NASDAQ
$2.10
-$0.22 (-9.48%)
At close: Nov 16, 2026, 4:00 PM ET
$2.13
+$0.03 (+1.37%)
After-hours:
Nov 16, 2026, 7:54 PM ET
-9.48%
(1D)No price chart data available for 1D timeframe.
Rating
42.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #467/1021 (Top 46%)
Key Statistics
Market Data
Market Cap $267.48M
1D Range
2.10 2.31
52W Range
0.85 3.95
Valuation (TTM)
PE -4.57
PB 2.29
EV/EBITDA -3.83
Valuation (NTM)
Forward PE N/A
Forward PEG 0.66
Price Target $3.50
Cash Flow
FCF Yield -20.6%
SBC Adj. FCF Yield -22.6%
SBC Impact -9.6%
Margins
Gross Margin -362.5%
Operating Margin -15105.7%
FCF Margin -13003.5%
Growth (CAGR)
Revenue 3Y | 5Y 150.0% |
100.0%
Dil EPS 3Y | 5Y 9.9% |
1.0%
FCF 3Y | 5Y 5.2% |
-2.9%
Returns
ROA -39.3%
ROE -42.7%
ROIC -44.7%
Financial Health
Net Cash
$86.58M
Current Ratio 9.25
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. Th...
Sector Healthcare
Industry Biotechnology
Employees 128
IPO Date Aug 7, 2020
Website www.nautilus.bio
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Oct 27, 2026
EPS
-$0.12
Beat +14.29%
YoY:
-9.09% REV
$234K
Beat +13.45%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$3.50
Upside
+66.67%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NAUT